The use of monoclonal antibodies (mAbs) to block either programmed cell death 1 (PD-1) or anti-programmed cell death ligand 1 (PD-L1) prevents the downregulation of T cell effector function, allowing T cells to mediate tumor cell death. Here, CD274 is linked to neoplasm.